胸苷激酶1（TK1）在骨肉瘤中的表达及其临床病理意义

中国临床解剖学杂志 ›› 2013, Vol. 31 ›› Issue (5): 564-567.

胸苷激酶1（TK1）在骨肉瘤中的表达及其临床病理意义

许美权^1,2,3，　王大平^1,2,3，　熊建义^1，2,3，　关弘²，　吴俊辉²，
黄雨华²，　朱伟民²，　李伟²，　杨雅洁²，　张继君²

1，广州医科大学，广州 510182；　2.深圳市第二人民医院，深圳 518035；
3，深圳市骨组织工程重点实验室，深圳 518035

收稿日期:2013-04-09 出版日期:2013-09-25 发布日期:2013-10-16
通讯作者: 王大平，教授，主任医师，E-mail:dapingwang1963@qq.　com E-mail:xumeiquan@126.com
作者简介:许美权（1981-），男，广东潮安人，主管技师，在职研究生，主要研究方向：骨肿瘤，Tel:0755-83366388-2234
基金资助:
深圳市科技研发资金深港创新圈(JSE2010071900071A)；深圳市战略性新兴产业发展专项资金（ZDSY20120614154551201）

Expression of Thymidine kinase 1 (TK1) in osteosarcoma and its clinico-pathological significance

XU Mei-quan ^1,2,3, WANG Da-ping ^1,2,3, XIONG Jin-yi ^1,2,3, GUAN Hong ², WU Jun-hui ², HUANG Yu-hua ², ZHU Wei-min ², LI Wei ², YANG Ya-jie², ZHANG Ji-jun²

1.Guangzhou Medical University, Guangzhou 510182, China; 2. Shenzhen Second People's Hospital, Shenzhen 518035, China; 3. Shenzhen Tissue Engineering Laboratory, Shenzhen 518035, China

Received:2013-04-09 Online:2013-09-25 Published:2013-10-16

摘要/Abstract

摘要：

目的　探讨骨肉瘤肿瘤细胞胸苷激酶1（TK1）的表达状况及骨肉瘤患者血清TK1的水平，分析其临床病理意义。方法采用免疫组化MaxVision法检测40例骨肉瘤和20例骨巨细胞瘤组织标本中TK1的表达；点印迹免疫酶化学发光法检测20例骨肉瘤患者和20例骨外伤患者血清TK1的水平。结果　骨肉瘤肿瘤细胞TK1阳性信号位于胞浆及胞核，高级别骨肉瘤阳性率显著高于低级别骨肉瘤（P<0.05）；骨肉瘤肿瘤细胞TK1阳性率亦显著高于骨巨细胞瘤（P<0.05）；骨肉瘤患者血清TK1的水平(2.95±1.33)pmol/L（0.97~7.25 pmol/L）高于外伤除外肿瘤患者(0.89±0.51) pmol/L (0.32~2.58 pmol/L)，两者差异具有显著性统计学意义（P<0.05）。结论　TK1在骨肉瘤与骨的良性病变的鉴别诊断中具有一定的意义。此外，TK1在骨肉瘤患者血清中可被检测到较高的水平，是一项检测骨肉瘤增殖活性较灵敏的指标。

关键词: 胸苷激酶1, 骨肉瘤, 免疫组化, 化学发光

Abstract:

Objective To investigate the expression ofTK1 in osteosarcoma tumor cells and the TK1 level of TK1 in the serum of patients with osteosarcoma, and analyze their clinico-pathological significances. Methods　40 cases of osteosarcoma and 20 cases of giant cell tumor were included in this study. Immunohistochemical staining of TK1 was performed on the tumor tissue by MaxVision method. Serum TK1 level in 20 patients with osteosarcoma and 20 patients with bone trauma was tested by chemiluminescence dot blot enzyme chemistry. Results The reactivity assessed was in cytoplasm and nuclei. The positive rate of TK1 in high grade osteosarcoma was significantly higher than that in low grade osteasarcoma(P<0.05); The positive rate of TK1 in osteasarcomais was higher than that in giant cell tumor, and the difference was statistically significant(P<0.05). In addition, the serum TK1 content in patients with osteosarcoma is significantly higher than that in patients with bone traumatic [2.95 (0.97-7.25) pmol/Lvs 0.89 (0.32-2.58) pmol/L,P<0.05]. Conclusion TK1 has a certain value in the differential diagnosis of osteosarcoma from benign bone lesions. High level of TK1 can be tested in the serum in patient with osteosarcoma, and it seems that TK1 is a sensitive indicator for testing osteosarcoma proliferation.

Key words: Thymidine kinase 1, Osteosarcoma, Immunohistochemical, Chemiluminescence

中图分类号:

R738.1

许美权, 王大平, 熊建义, 关弘, 吴俊辉, 黄雨华, 朱伟民, 李伟, 杨雅洁, 张继君. 胸苷激酶1（TK1）在骨肉瘤中的表达及其临床病理意义[J]. 中国临床解剖学杂志, 2013, 31(5): 564-567.

HU Mei-Quan, WANG Da-Beng, XIONG Jian-Xi, GUAN Hong, TUN Dun-Hui, HUANG Yu-Hua, SHU Wei-Min, LI Wei, YANG Ya-Ji, ZHANG Ji-Jun. Expression of Thymidine kinase 1 (TK1) in osteosarcoma and its clinico-pathological significance[J]. Chinese Journal Of Clinical Anatomy, 2013, 31(5): 564-567.

参考文献

[1] Gesing A, Modrzejewska H, Karbownik M, et al. Thymidine kinase and adenosine kinase activities in homogenates of thyroid lobes in enmity roidectomized rats, effects of melatonin in vitro
[J]. Neuro Endocrinol Lett, 2000, 21 (6) : 453-459.

[2] Struthers H, Viertl D, Kosinski M, et al. Charge dependent substrate activity of C3' and N3 functionalized, organometallic technetium and rhenium-labeled thymidine derivatives toward human thymidine kinase 1
[J]. Bioconjug Chem, 2010, 21(4):622-634.

[3] Topolcan O, Holubec L Jr．The role of thymidine kinase in cancer diseases
[J]．Expert Opin Med Diagn, 2008, 2(2):129-141.

[4] Chen Z, Zhou H, Li S, et al．Serological thymidine kinase1(STK1) indicates an elevated risk for the development of malignant tumours
[J]．Anticancer Res, 2008, 28(6B):3897-3907.

[5] Green FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG. Morrow. AJCC Cancer Staging Manual
[M]. 6th ed. Springer. New York. 2002:133-137.

[6] Sobin LH, Witteking C. UICCTNM Classification of Malignant Tumours
[M].6th ed.Wiley: New York. 2002:735-737.

[7] Bradshaw Jr HD, Deininger PL. Human thymidine kinase gene:molecular cloning and nucleotide sequence of a cDNA expressible in mammalian cells
[J]. Mol Cell Biol, 1984,4(11):2316-2320.

[8] Welin M, Kosinska U, Mikkelsen N, et al. Structures of thymidine kinase 1 of human and mycoplasmic origin
[J]. Proc Natl Acad Sci USA, 2004,101(52):17970-17975.

[9] Mao Y, Wu J, Wang N, et al. A comparative study: immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer
[J]. Cancer Invest, 2002, 20(7-8):922-931.

[10] 李艳,张平安,邹力,等.免疫印迹法测定乳腺肿瘤患者胸苷激酶
[J].中华检验医学杂志,2000, 23(6):334-336.

[11]Khan Z, Knecht W, Willer M, et al．Plant thymidine kinase 1 a novel efficient suicide gene for malignant glioma therapy
[J]．Neuro Oncol, 2010,12(6):549-558.